CRL
Charles River Laboratories International, Inc.
IndustrialsKey Metrics
Factor Lens
Seasonal Performance
Financial Trends
Revenue & Net Income
Earnings Per Share
Margins
Cash Flow
Company Overview
Charles River Laboratories International, Inc. is a leading, full-service, non-clinical global drug development partner with a mission to create healthier lives. The company… operates through three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment provides foundational research models and services, including purpose-bred rodents and large research models, plus research model services and cell solutions. The DSA segment provides outsourced drug discovery research, non-clinical and clinical bioanalytical activities, and regulatory-required safety testing of drugs, vaccines, chemicals, and medical devices. The Manufacturing segment comprises Microbial Solutions, which provides in vitro testing methods for pharmaceuticals and consumer products, and Biologics Solutions, which provides specialized testing and contract development and manufacturing (CDMO) services for cell and gene therapies. The company serves major pharmaceutical companies, biotechnology companies, contract research organizations, hospitals, academic institutions, and government agencies globally, with operations in over 120 sites across more than 20 countries. In fiscal year 2025, total revenue was $4.0 billion.
- Name
- Charles River Laboratories International, Inc.
- Industry
- Industrials
- CEO
- James C. Foster · Chair, President and Chief Executive Officer
- Employees
- 18,500 as of 2025-12-27
- IPO Date
- 2015-11-04
- Phone
- (781) 222-6000
- Address
- 251 Ballardvale Street, Wilmington, MA 01887
- Website
- www.criver.com
Key Executives
| Name | Title | FY Pay |
|---|---|---|
| Virginia M. Wilson | Retired Senior Executive Vice President and Chief Financial Officer, TIAA | — |
| George Llado, Sr. | Former Senior Vice President and Chief Information Officer, Alexion Pharmaceuticals | — |
| Nancy C. Andrews | Executive Vice President and Chief Scientific Officer, Boston Children's Hospital | — |
| Birgit Girshick | Corporate Executive Vice President & Chief Operating Officer | — |
| James C. Foster | Chair, President and Chief Executive Officer | — |
Latest News
- 2026-04-23
-
2026-04-21
Charles River Highlights Effectiveness of VCGs in Toxicology businesswire.com
- 2026-04-14
- 2026-04-09
- 2026-04-08
- 2026-04-06
- 2026-03-31
- 2026-03-20